HK1257677A1 - 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途 - Google Patents

咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途

Info

Publication number
HK1257677A1
HK1257677A1 HK19100041.8A HK19100041A HK1257677A1 HK 1257677 A1 HK1257677 A1 HK 1257677A1 HK 19100041 A HK19100041 A HK 19100041A HK 1257677 A1 HK1257677 A1 HK 1257677A1
Authority
HK
Hong Kong
Prior art keywords
quinolin
imidazo
compounds
treating cancer
cancer
Prior art date
Application number
HK19100041.8A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Thomas Anthony Hunt
Andrew John Eatherton
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1257677A1 publication Critical patent/HK1257677A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19100041.8A 2015-11-05 2019-01-03 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途 HK1257677A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519568.8A GB201519568D0 (en) 2015-11-05 2015-11-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PCT/EP2016/076416 WO2017076898A1 (en) 2015-11-05 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
HK1257677A1 true HK1257677A1 (zh) 2019-10-25

Family

ID=55132360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100041.8A HK1257677A1 (zh) 2015-11-05 2019-01-03 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途

Country Status (22)

Country Link
US (1) US20180280377A1 (zh)
EP (1) EP3370722A1 (zh)
JP (1) JP2019501873A (zh)
KR (1) KR20180073684A (zh)
CN (1) CN108348515A (zh)
AU (1) AU2016348620B2 (zh)
BR (1) BR112018007811A2 (zh)
CA (1) CA3002717A1 (zh)
CL (1) CL2018001171A1 (zh)
CO (1) CO2018004933A2 (zh)
CR (1) CR20180308A (zh)
DO (1) DOP2018000115A (zh)
GB (1) GB201519568D0 (zh)
HK (1) HK1257677A1 (zh)
IL (1) IL258828A (zh)
MX (1) MX2018004954A (zh)
NI (1) NI201800051A (zh)
PE (1) PE20181346A1 (zh)
PH (1) PH12018500957A1 (zh)
RU (1) RU2018120492A (zh)
SV (1) SV2018005680A (zh)
WO (1) WO2017076898A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
KR20210061337A (ko) 2018-09-14 2021-05-27 수저우 잔롱 파마 리미티드 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도
RU2771314C1 (ru) * 2018-09-30 2022-04-29 Медшайн Дискавери Инк. Производные хинолинпирролидин-2-она и их применение
BR112022001067A2 (pt) * 2019-07-30 2022-05-24 Xrad Therapeutics Inc Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
CA2763821A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (zh) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
CN108348515A (zh) 2018-07-31
DOP2018000115A (es) 2018-06-30
CL2018001171A1 (es) 2018-10-12
BR112018007811A2 (pt) 2018-10-30
CO2018004933A2 (es) 2018-08-10
AU2016348620B2 (en) 2019-05-02
KR20180073684A (ko) 2018-07-02
PH12018500957A1 (en) 2018-11-19
JP2019501873A (ja) 2019-01-24
US20180280377A1 (en) 2018-10-04
AU2016348620A1 (en) 2018-06-14
WO2017076898A1 (en) 2017-05-11
PE20181346A1 (es) 2018-08-22
CR20180308A (es) 2018-10-02
IL258828A (en) 2018-06-28
NI201800051A (es) 2018-07-30
CA3002717A1 (en) 2017-05-11
SV2018005680A (es) 2018-06-22
GB201519568D0 (en) 2015-12-23
RU2018120492A (ru) 2019-12-05
EP3370722A1 (en) 2018-09-12
MX2018004954A (es) 2018-07-06
RU2018120492A3 (zh) 2020-01-30

Similar Documents

Publication Publication Date Title
HRP20180697T1 (hr) Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka
HK1257678A1 (zh) 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
HK1257677A1 (zh) 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL266245B (en) History of 9,8,7,6-tetrahydro-3h-pyrazolo[3,4-f]isoquinoline useful in cancer treatment
IL259162B (en) fgfr2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
IL266198A (en) Liposomal formulation for use in cancer treatment
IL269272A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
EP2976342A4 (en) 2-SUBSTITUTED IMIDAZO [4,5-D] PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
GB201516220D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer
GB201613403D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer